Resumen de: WO2023286977A1

The present invention discloses an anti-allergic composition using water-solubilized mastic gum or a Lindera glauca Blume extract, wherein the composition has degranulation-suppressing activity when used to treat rat basophilic leukemia (RBL-2H3), which is an obese cell line activated by IgE and antigen (DNP-BSA).

Resumen de: WO2023288100A1

Provided herein are liposomes comprising B-cell lymphoma (Bel) protein inhibitors, compositions comprising such liposomes, and methods using such formulations for treating hyperproliferative disorders.

Resumen de: WO2023288240A1

Embodiments of the invention related generally to antisense oligonucleotides (ASOs) and, more particularly, to compositions and methods for regulating protein synthesis using ASOs. In one embodiment, the invention provides a method of treating a patient diagnosed with myelodysplastic syndrome (MDS) comprising: administering to the patient an amount of an antisense oligonucleotide (ASO) targeted to a nucleic acid molecule encoding JAK2 (ASO-T-JAK2) compound effective to treat such disease.

Resumen de: AU2021263926A1

Methods of treating multiple myeloma by administering a multispecific antibody to a patient in need are provided. Methods of making such antibodies, and compositions, including pharmaceutical compositions, comprising such antibodies, are also provided.

Resumen de: WO2023287797A2

This disclosure provides a method of treating cancer or a blood disorder disease in a patient, the method comprising administering a therapeutically effective amount of a combination of compounds comprising (1) a hypomethylating agent (HMA) and (2) an XP01 inhibitor to a patient. The XP01 inhibitor can be Valtrate or Caffeic acid phenyl ester (CAPE) or salt, hydrate or derivative thereof. Cancers that may be treated with this method include acute myeloid leukemia (AML) particularly leukemias in which a MLL mutation is present or one or both of an NPM1 mutation and an FLT3 mutation is present.

Resumen de: AU2021422370A1

Disclosed are a compound as represented by the following general formula (I) or a pharmaceutically acceptable salt thereof. Further disclosed are a method for preparing the above-mentioned compound and the use thereof in preventing and/or treating diseases related to cancer or tumors, in particular diseases such as breast cancer, prostate cancer, lung cancer, multiple myeloma, leukemia, gastric cancer, ovarian cancer, colon cancer, liver cancer, pancreatic cancer and human glioma. The compound of the present invention is expected to be developed into a new generation of anticancer drugs.

Resumen de: WO2023287128A1

The present invention relates to an indazole yl benzimidazole derivative or a pharmaceutically acceptable salt thereof, a preparation method thereof, a composition, for preventing, relieving or treating a protein kinase-related disease, comprising the derivative or the salt as an active ingredient, and the like. The indazole yl benzimidazole derivative of the present invention selectively inhibits Fms-like tyrosine kinase 3 (FLT3) when administered to a subject, and thus may be utilized for preventing, relieving or treating cancers including leukemia, inflammatory diseases including arthritis, or osteoporosis.

Resumen de: AU2021298106A1

The present disclosure is directed to a combination therapy comprising an antibody or antibody fragment specific for CD19 and a polypeptide that blocks the SIRPα-CD47 innate immune checkpoint for use in the treatment of cancer, in particular hematological cancer such as leukemia or lymphoma.

Resumen de: US2023014026A1

The present disclosure is directed to a combination therapy comprising an antibody or antibody fragment specific for CD19 and a polypeptide that blocks the SIRPα-CD47 innate immune checkpoint for use in the treatment of cancer, in particular hematological cancer such as leukemia or lymphoma.

Resumen de: US2023018688A1

The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TOR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.

Resumen de: US2023019140A1

Disclosed herein is a method of treating cancer, such as multiple myeloma, involving the combination of an anti-BCMA antigen binding protein (e.g., an anti-BCMA antibody) and a proteasome inhibitor (e.g. bortezomib). The combinations can also include an anti-inflammatory compound (e.g. dexamethasone).

Resumen de: US2023016357A1

The present invention provides compositions, systems, kits, and methods for combining a. single myeloma cell and a single B-cell (e.g., from an animal exposed to a desired antigen) via discrete entity (e.g., droplet) microfluidics. In certain embodiments, a microfluidic device is used to merge a discrete entity containing a B-cell, and a discrete entity containing a myeloma cell, and a discrete entity containing gellable material, at a merger region via a trapping element in order to generate a combined discrete entity. In further embodiments, the combined discrete entity is treated such that a gelled discrete entity is formed.

Resumen de: US2023020729A1

The presently disclosed subject matter provides for methods and compositions for treating a neoplasia (e.g., multiple myeloma). It relates to chimeric antigen receptors (CARs) that specifically target Fc Receptor-like 5 (FcRL5), e.g., domain 9 of FcRL5, and immunoresponsive cells comprising such CARs. The presently disclosed FcRL5-targeted CARs have enhanced immune-activating properties, including anti-tumor activity.

Resumen de: US2023020894A1

Provided herein are isolated anaplastic lymphoma kinase (ALK) peptides that are fragments of the cytoplasmic portion of an ALK protein shared by cancers having an ALK rearrangement and cancers expressing the ALK protein, that bind a human leukocyte antigen (HLA), and elicit an immune response against one or more ALK-positive cancers. Also provided are isolated ALK peptides that are modified with an amphiphilic conjugate to increase T-cell expansion and greatly enhance anti-tumor efficacy. The invention also provides polynucleotides encoding isolated ALK peptides, vaccines comprising an isolated ALK peptide or polynucleotide, immunogenic compositions thereof, and kits for administering the same. Methods of treatment and methods of generating an immune response in a subject by administering the ALK-specific peptide antigens, immunogens, vaccines, or immunogenic compositions thereof are provided.

Resumen de: US2023019650A1

The present invention relates to a chimeric antigen receptor (CAR) which comprises an antigen-binding domain which selectively binds TCR beta constant region 1 (TRBC1) or TRBC2; cells; such a T cells comprising such a CAR; and the use of such cells for the treatment of a T-cell lymphoma or leukaemia in a subject.

Resumen de: US2023018197A1

The present disclosure provides formulations of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), intraocular lymphoma (e.g., PVRL), and intraocular inflammation.

Resumen de: US2023018888A1

Antibodies, fragments thereof and fusion proteins that specifically bind to ADGRE2, are described, as well as methods of making and using such antibodies. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various autoimmune diseases and cancers, including, for example, acute myeloid leukemia.

Resumen de: US2023017743A1

The present disclosure provides formulations of methotrexate for ocular administration, including intravitreal administration, and use of the formulations for treating proliferative vitreoretinopathy (PVR), intraocular lymphoma (e.g., PVRL), and intraocular inflammation.

Resumen de: US2023016709A1

Methods for detection, diagnosis, prognosis, theragnosis, and targeted therapy of a PRSS21-overexpressing condition (e.g., cancer), in particular, PRSS21-overexpressing acute myeloid leukemia of the AMKL subtype.

Resumen de: AU2021285715A1

Provided herein are compounds of Formula (I) that are dual inhibitors of kinases and bromo-domain proteins. The disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, particularly, the treatment of multiple myeloma cancers, and to related uses.

Resumen de: AU2021271694A1

The disclosure is directed to crystalline forms of the compound of Formula I: Formula (I), and pharmaceutically acceptable salts thereof. Pharmaceutical compositions comprising compounds of Formula I as well as methods of their use and preparation, are also described.

Resumen de: WO2022220841A1

A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.

Resumen de: WO2021182897A1

The present invention relates to: a pharmaceutical composition for preventing or treating NK/T-cell lymphoma, comprising a phosphodiesterase type 5 inhibitor, the pharmaceutical composition being for inhibiting the reactivation of the Epstein-Barr virus (EBV) induced by a HDAC inhibitor; an anticancer therapy adjuvant composition; and a health functional food. By using the pharmaceutical composition for preventing, alleviating or treating NK/T-cell lymphoma, according to the present invention, EBV reactivation, induced by a HDAC inhibitor used as an anticancer agent for NK/T-cell lymphoma, may be inhibited, and thus side-effects of the HDAC inhibitor may be reduced, and an anticancer effect may be notably increased. Thus, the present invention may be widely used in the pharmaceutical industry on the basis of said effects.

Resumen de: CA3175913A1

Provided herein are liposomes comprising B-cell lymphoma (Bcl) protein inhibitors, compositions comprising such liposomes, and methods using such formulations for treating hyperproliferative disorders.

Resumen de: KR20230007017A

본 발명은 급성 골수성 백혈병의 예후에 특이적인 바이오마커에 관한 것으로, 본 발명에 따르면, 본 발명의 마이크로 RNA 마커들은 급성 골수성 백혈병의 예후에 따라 특이적으로 그 발현이 상향 또는 하향 조절되므로, 이를 급성 골수성 백혈병의 예후 진단 용도로 유용하게 활용할 수 있으며, 특히, 세포가 아닌 세포외소포에서 상기 마커들의 발현 변화를 확인하기 때문에, 종래의 급성 골수성 백혈병 세포를 이용한 검사 방법에 비해 시간과 비용이 절약된 효율적인 효과가 있다.